

Abraxane® (paclitaxel protein-bound)	112
acupuncture, traditional Chinese medicine, and cano	er 58
ado-trastuzumab emtansine (Kadcyla®)	113
Adriamycin® (doxorubicin)	111,174,182,223
Adrucil® (fluorouracil, 5-FU)	110,174,182,189,202,223,268
Afinitor® (everolimus)	268
AICR/WCRF: personal recommendations for cancer	prevention 17,54,61,249
alcohol 17-	-18,19,92,178,201,232,249,268-269
Aldesleukin® (interleukin-2 or IL-2)	102
Alimta® (pemetrexed)	214,269
alkaline diet	63
Alkeran® (melphalan)	110,214,268
aloe vera	69-70
alternative diets for cancer prevention	62-65
altretamine (Hexalen®)	214
American Cancer Society Guidelines	54,61,249
American Cancer Society Survivorship Guidelines	249
American Joint Committee on cancer tumor grading	10
anal cancer	196-197
anastrozole (Arimidex®)	103,174
androgen deprivation therapy (ADT) and prostate ca	ncer 230
animal food/products	17,249

angiogenesis inhibitors	100-101
anorexia	13,89,115
anticancer nutrition/diets	54,63-65
anti-dumping diet	183,221,257-260
antioxidants	10,70-71
anti-thymocyte globulin (Thymoglobulin®)	160
appendices 1: public health guidelines for cancer prevention/survivorship 2: assessing performance status 3: diet and nutrition guidelines after intestinal surgery 4: anti-dumping diet 5: diet and nutrition guidelines after ileostomy placement 6: MCT margarine and MCT vinaigrette dressing 7: overview of ketogenic diet	249-250 251 253-255 257-260 261-263 265 266
8: drug, nutrient, food, dietary supplement interactions with cancer medications9: bowel regimen	267-270 271
Aromasin® (exemestane)	103,175,268
artificial hydration and nutrition in palliative/hospice care	243-244
ARA-C, cytarabine (Cytosar-U®)	110
Arimidex® (anastrozole)	103,174
Association of Community Cancer Center Guidelines	48-49
Astagraf XL®, Prograf® (tacrolimus)	160
Avastin® (bevacizumab)	101,167,175,182,189
axitinib (Inlyta®)	267
ayurveda	53
azacitidine (Vidaza®)	110

Oncology Nutrition a dietetic practice group of the Academy of Nutrition

Index: Oncology Nutrition for Clinical Practice	ear Academy of Nutrition right and Dietetics
Azasan®, Imuran® (azathioprine)	160
azathioprine (Imuran®, Azasan®)	160
BCNU® (carmustine)	109
beclomethasone dipropionate (Beconase AQ®, Qvar®)	160
Beconase AQ®, Qvar® (beclomethasone dipropionate)	160
bendamustine (Treanda®)	109
beta carotene	67,71
beta glucans	67
bexarotene (Targretin®)	267
bevacizumab (Avastin®)	101,167,175,182,189
bicalutamide (Casodex®)	103
billing and reimbursement of oncology nutrition services	49-50
bioactive food components & carcinogenesis	12,79-80
biotherapy - angiogenesis inhibitors - cancer vaccine therapies - categories of biotherapy agents - cytokines - monoclonal antibodies - principles of biotherapy - protein-targeted therapies	100-101 100 99 100,102 99-100,113 99 100-101
black cohosh	75
Blenoxane® (bleomycin)	111,202
bleomycin (Blenoxane®)	111,202
body fatness	13,15,17

body weight	249
bone and muscle health (and cancer survivorship)	13,88-89,93,161
bortezomib (Velcade®)	267
bowel obstruction/malignant bowel obstruction	88,216
bowel regimen	271
brachytherapy - general review - general types of brachytherapy placement - possible acute & late-occurring side effects of brachytherapy - type and source duration of brachytherapy	104 106 107 106
brain cancer/tumors - chapter (medical nutrition therapy for brain cancer) - abnormal swallowing - adverse effects of medications - calorie restriction - characteristics/treatments - corticosteroid treatment - end-of-life care - goals for nutritional care - ketogenic diet - nutrition risk screening & assessment	165-169 167 167 168 165-166 167 168 167 168
breads, grains & cereals	249,258,262
breast cancer - chapter (medical nutrition therapy for breast cancer) - diet (composition, fatty acids, fiber, soyfood, green tea) - hormone receptive cancers - lymphedema - medical nutrition therapy - medical treatments - nutrition impact symptoms of common treatment agents - nutritional needs - nutritional status - risk factors - staging - tips to reduce breast cancer risk and progression	171-180 176-178 172 175 176 172-173 173-175 176 175-176 171 172
breastfeeding	17,19



budesonide (Entocort EC®, Uceris® for oral; others for inhaled for	rm) 160
Budwig Diet	63
busulfan (Myleran®)	109,267
С	
cachexia	28,144
calcium	70-71,193,230-232
calorie restriction	43,168
Camptosar® (irinotecan)	167,182,189,214,223
cancer and nutrition - chapter - carcinogenesis and bioactive food components - bioactive food components influence carcinogenesis - medical treatments - potential nutrition-related issues & outcomes across the cancer of screening - staging - statistics	9-14 12 12 11-12 continuum 13 9 9-10 9

cancer drugs:

All cancer drugs addressed in *Oncology Nutrition for Clinical Practice* are listed individually in this index. Both the generic name and common brand names are listed for each drug. However, some drugs have multiple brand names, and in these cases not all brand names are included. In addition, all drugs addressed in chapter 11, "nutritional effects of cancer treatment: chemotherapy, biotherapy, hormone therapy and radiation therapy" and appendix 8, "drug/nutrient/food/dietary supplement interactions with cancer medications" are listed under each title.

Oncology Nutrition for Clinical Practice also includes several tables addressing cancer medications/drugs used for various diagnoses. These are found on the following pages:

- breast cancer	173-175
- brain tumors	167
- esophageal cancer	182
- graft versus host disease	160
- GI cancers	189
- head and neck cancers	202
- ovarian cancer	214



- pancreatic and bile duct cancer	223
cancer prevention - chapter - AICR/WCRF personal recommendations and cancer prevention - alcoholic drinks and cancer prevention - body fatness/abdominal fatness and cancer prevention - breastfeeding and cancer prevention - dietary supplements and cancer prevention - emerging topics and cancer prevention (e.g., soy, omega-3 fatty acids) - foods processed with salt/sodium and cancer prevention - physical activity and cancer prevention - plant-based diet and cancer prevention - public health guidelines for cancer prevention & survivorship	15-24 17 18-19 15-16 19 20-21 19 16 16-18 249
- red and processed meats and cancer prevention	18
(also see information under "nutrition and cancer prevention") cancer staging - summary of TNM staging classification system	9-10 10
cancer survivorship - chapter - AICR/WCRF personal recommendations including those for cancer survi - biology of weight change in survivors - diet and lifestyle recommendations for colorectal cancer survivors - diet and nutrition recommendations for cancer prevention/survivorship - dietary guidance & survivorship - dietary intervention studies in cancer survivors - dietary intervention for bone and muscle health - dietary supplementation for survivors - prostate cancer survivorship - resources for cancer survivors - public health guidelines for cancer prevention & survivorship - select randomized clinical trials on nutrition & survivorship - survivorship for ovarian cancer	87-96 ivors 17 91 193 82 92-93 91-92 93 93-94 232 90 249 92 216
cancer treatments - angiogenesis inhibitors - biotherapy - brachytherapy - chemotherapy - cytokines - general review - goals of cancer therapy - hormone therapy/hormonal agents	101 99 106 98,109-112 102 11-12 98 101,103

monoclonal antibodiesradiation therapyradiation therapy and breast cancerradiation therapy and head and neck cancer	113 102 172-173 202
capecitabine (Xeloda®)	110,173,182,189,214,223,267
carbamazepine (Tegretol®)	167
carboplatin (Paraplatin®)	109,182,189,202
carcinogenesis	10,12,79
carmustine (BCNU®)	109
Casodex® (bicalutamide)	103
CCNSB®, CeeNU®, Gleostine® (Iomustine systemic)	167
CeeNU®, CCNSB®, Gleostine® (Iomustine systemic)	167
Cellcept® (mycophenolate mofetil)	160
Certified Specialist in Oncology Nutrition (CSO)	49
cetuximab (Erbitux®)	113,182,189,202,267
chemotherapy - classification, mechanism of action, administration, side	11,98-99,109-112 e effects 109-112
chlorambucil (Leukeran®)	109,267
CIPN and glutamine (CIPN = chemotherapy induced peripheral neuropathy)	211
cisplatin (Platinol®)	109,182,189,202,214,223,267
coenzyme Q10	70,75
colorectal cancer	88,191-193
constipation	116
corticosteroids	160,167

Cosmegen® (dactinomycin)	111
curcumin	57,70,75
cyclophosphamide (Cytoxan®, CTX)	109,173,214,267
cyclosporine (Sandimmune®)	160
cytarabine, ARA-C (Cytosar-U®)	110
cytokines - examples of cytokines - general definition - possible side effects and nutritional implications of cytokines	102 100 102
Cytosar-U® (ARA-C, cytarabine)	110
Cytoxan® (CTX, cyclophosphamide)	109,173,214,267
D dacarbazine (DTIC-dome®) dactinomycin (Cosmegen®)	109 111
dairy foods (r/t calcium)	230-232,262,268
dasatinib (Sprycel®)	267
daunomycin® (daunorubicin)	111
daunorubicin (Daunomycin®)	111
Decadron® (dexamethasone)	167
deferasirox (Exjade®)	267
defining and developing an oncology nutrition program in a cancer cer- chapter - billing and reimbursement - defining and oncology nutrition program - components of an oncology nutrition program - measuring outcomes of nutrition care - organizational structures for clinical nutrition services - specifics of nutrition programming	enter 47-51 49-50 47 47-48 51 49 50-51

Index: Oncology Nutrition for Clinical Practice	a dietetic practice group of the eqt* Academy of Nutrition right. and Dietetics
staffing an oncology nutrition programstandards of practice in oncology nutrition carestandards of professional performance for oncology RDs	48 49 49
denosumab (Xgeva®, Prolia®)	113
Depakote® (divalproex sodium)	167
dexamethasone (Decadron®)	167
diabetes	221,224
diarrhea	88,116,260
diet history and nutrition risk screening	27
diet (and cancer/cancer symptom reduction / prevention / survivorship - anti-dumping diet - breast cancer risk reduction - cancer prevention and survivorship - graft versus host disease - ileostomy placement	183,190,257-259 178 17,82,91-94,249 161 261-263
 immunosuppressed patients intestinal surgery lifestyle recommendations— colorectal cancer post-symptom, post-treatment diet therapy (for survivorship) prostate cancer survivorship 	159 253 193 90 232
diets for cancer prevention/treatment/survival - categories of functional foods - diets and functional foods for prevention/treatment/survival - functional food sources of select cancer-fighting compounds - integrative use of diets in cancer treatment/survival - integrative use of functional foods in cancer treatment/survival - omega-3 fatty acids - role of functional foods in the health care continuum	61-68 66 62-68 67 62-65 66-67 72 61
dietary fat and cancer prevention/survivorship	249
dietary supplements - and cancer survivors - antioxidant supplements and cancer - general discussion - interactions between cancer treatments & dietary supplements - RCTs on antioxidant supplementation and cancer risk	68-78 70-71 55-56 69-70 71



 RCTs on vit D/calcium supplements and colon, breast, & pro-resources on dietary supplements safety profile of dietary supplements vitamin D, calcium and cancer 	71 72 69 70-71
Dilantin® (phenytoin)	167
divalproex sodium (Depakote®)	167
docetaxel (Taxotere®)	112,173,182,189,202,223
Doxil® (doxorubicin liposomal)	111,189,214
doxorubicin (Adriamycin®)	111,174,182,223
doxorubicin liposomal (Doxil®)	111,189,214
drug/nutrient/food/dietary supplement interactions with cance (® = brand name) axitinib (Inlyta®) bexarotene (Targretin®) bortezomib (Velcade®) busulfan (Myleran®) capecitabine (Xeloda®) cetuximab (Erbitux®) chlorambucil (Leukeran®) cisplatin (Platinol®) cyclophosphamide (Cytoxan®) dasatinib (Sprycel®) deferasirox (Exjade®) erlotinib (Tarceva®) everolimus (Afinitor®) exemestane (Aromasin®) fluorouracil (5-FU or Adrucil®) gefitinib (Iressa®) imatinib mesylate (Gleevec®) lapatinib (Tykerb®) melphalan (Alkeran®) mercaptopurine (6-MP or Purinethol®) methotrexate (Folex® or Rheumatrex®) nilotinib (Tasigna®) oxaliplatin (Eloxatin®) panitumumab (Vectibix®) pemetrexed (Alimta®)	267 267 267 267 267 267 267 267 267 267
procarbazine hydrochloride (Matulane®)	269



regorafenib (Stivarga®) Note/clarification of information in the first printing of this book: high the absorption of regorafenib/stivarga®. One study (with 24 health medicine was better absorbed when taken with a meal providing 319 calories as compared with a meal providing 54.6 grams of fat a result, most physicians ask patients to take this drug in the more meal providing < 8 grams of fat. sipuleucel-T (Provenge®) sorafenib (Nexavar®) streptozocin (Zanosar®) sunitinib (Sutent®) tamoxifen (Nolvadex®) temozolomide (Temodar®) temsirolimus (Torisel®) thalidomide (Thalomid®) vinblastine (Velban®) vincristine (Oncovin®) zoledronic acid (Zometa®)	hy men) found that this 8.2 grams of fat and t and 945 calories. As
drug:supplement interactions of interest to cancer survivors	70
DTIC-dome® (dacarbazine)	109
dumping syndrome	183,190,257-260
dysphagia	88,117,236
dysthesia	110,268
_	
E early dumping	257,260
Eastern Cooperative Oncology Group (ECOG) status	251
extracorporeal photopheresis (ECP)	160
Ellence® (epirubicin)	111,174,182,189
Eloxatin® (oxaliplatin)	110,182,189,223,268
endocrine and exocrine effects of neuroendocrine tumors	139
energetics, exercise and cancer - chapter	41-46

 calorie restriction and cancer prevention cancers associated with lifestyle habits exercise and cancer survivors exercise during cancer treatment obesity and cancer risk post-treatment exercise and cancer outcomes 	43 41 43 44 41
 promoting physical activity recommendations for physical activity for cancer survivors weight and cancer outcomes weight during treatment and post-treatment 	44 43 42 43
energy balance and cancer	15-16,41-42,,44,54,90,93
energy density (definition)	16
energy needs - adults - pediatrics	35-38 147-149
enteral nutrition - administration - advanced cancer - blenderized tube feeding recipe - complications - contraindications - esophageal cancer - feeding routes and considerations - formulations and modular nutrients - gastric cancer - gastric residual volumes - head and neck cancer - hematopoietic cell transplantation - indications/benefits in the oncology setting - medication interactions - pediatric patients	125 245 132 125-127 124 184-184 124 124-125 190 126 203-207 158-159 123 126 153
Entocort EC®, Uceris® for oral; others for inhaled form (bude	esonide) 160
epigenetics and cancer	82
epirubicin (Ellence®)	111,174,182,189
Erbitux® (cetuximab)	113,182,189,202,267
erlotinib (Tarceva®)	223,267



esophageal cancer - chapter (medical nutrition therapy for esophageal cancer) - anatomical changes in esophagectomy - dumping syndrome / anti-dumping diet - enteral nutrition - malnutrition - nutrition impact symptoms of common treatment agents - nutrition needs - nutrition risk screening and assessment - risk factors - surgery	181-186 183 183 184-185 184 182 184 184 181-182
esophagitis (symptom management)	119
essiac/flor-essence	63
etoposide (Vepesid®, VP-16)	112,214
Eulexin® (flutamide)	103
everolimus (afinitor®)	268
evidence-based cancer care	97
Evista® (raloxifene)	103
exemestane (Aromasin®)	103,175,268
Exjade® (deferasirox)	267
extracorporeal photopheresis (ECP)	160
<u>F</u> factors affecting response to cancer treatment	98
Fareston® (toremifene citrate)	103
Faslodex® (fulvestrant)	175
fasting	64
fatigue (symptom management)	89,118
langue (symptom management)	09,110

fats - fat (dietary) and cancer survivorship - fatty acids and breast cancer - oleic acid - omega-3 fatty acids - omega-9 fats	93 177 70 20,56,70,72,75,177,230,232 230,232
Femara® (letrozole)	103,175
fiber	67,177
flaxseed	21,75,232
Flor-Essence (Essiac)	63
Fludara® (fludarabine)	110
fludarabine (Fludara®)	110
fluorouracil (5-FU, Adrucil®)	110,174,182,189,202,223,268
flutamide (Eulexin®)	103
folic aid	268-269
fructo-oligosaccharides	67
fruits and vegetables	93,249,258,262
fulvestrant (Faslodex®)	175
functional foods - definition - in the health care continuum - functional food sources of cancer-fighting compounds	66 61 67
<u>G</u> gabapentin (Neurontin®)	167
gallbladder cancer	195-196
garlic	76
gastric cancer	188-190



gastrointestinal tract cancers (also see nutrition management for cancers of the gastrointes	187-199 stinal tract)
gefitinib (Iressa®)	268
gemcitabine (Gemzar®)	110,174,189,202,214,223
Gemzar® (gemcitabine)	110,174,189,202,214,223
genetic variations and cancer risk	81
genistein	67
Gerson Diet	64
ginger	76
gingko biloba	76
Gleevec® (imatinib mesylate)	268
Gleostine®, CeeNU®, CCNSB®) (Iomustine systemic)	167
glutamine	76,211
Gonzalez Regimen	64
goserelin (Zoladex®)	103,175
graft versus host disease	160-161
grapefruit/grapefruit juice	267-270
graphics - brain - colon - colorectal surgery resections - esophagectomy - head and neck - gallbladder - liver - lung - ovaries - parts of small intestines	165 139 192 183 201 195 139 209 213 138

Index: Oncology Nutrition for Clinical Practice	a detert practice group of the ear. Academy of Nutrition right. and Dietetics
prostate glandsites of nutrient absorptionstomachthyroid gland	229 187 137 235
green tea	21,57,178,232,267
H hand and foot syndrome	101,110-111,267-268
head and neck cancer (HNC) - chapter (medical nutrition therapy for HNC) - medical treatment - nutrition challenges/goals - nutrition implications of chemotherapy agents - nutritional phases of chemo-radiation treatment - oral toxicity scale (WHO) - risk factors	201-208 202-203 203 202 204-207 203 201
hematopoietic stem cell transplant (adults) - chapter (medical nutrition therapy for hematopoietic cell transplated diet for GI symptoms of graft versus host disease (GVHD) - diet for immunosuppressed patients - long-term complications/management - medical treatment for GVHD - nutrient considerations - nutrient needs - nutrition support - nutrition assessment	antation) 157-163 161 159 160-162 160 159-160 158 158-159
hemotpoietic stem cell transplant (pediatric)	153-154
hepatocellular cancer	194-195
Herceptin® (trastuzumab)	113,175,182,189
Hexalen® (altretamine)	214
hormonal agents used in cancer treatment	103
hormone-receptive breast cancers	172

hospice care

- chapter (nutrition management of oncology patients in palliative and hospice settings)	241-247
Hycamtin® (topotecan)	182,214
<u>I</u> ibritumomab tiuxetan (Zevalin®)	113
Idamycin® (idarubicin)	111
idarubicin (Idamycin®)	111
Ifex® (Ifosfamide)	109,202,214
Ifosfamide (Ifex®)	109,202,214
lleostomy (diet and nutrition guidelines)	261
imatinib mesylate (Gleevec®)	268
Imuran®, Azasan® (azathioprine)	160
inherited cancer syndromes	81-82
Inlyta® (axitinib)	267
integrative oncology: the role of nutrition - chapter - anti-cancer nutrition - components of an integrative oncology program - dietary supplements - nutraceuticals - pancreatic cancer - pediatric patients	53-60 54-55 53-54 55-56 56-57 223 152
integrative use of diets in cancer treatment/survival	62-65
integrative use of functional foods in cancer treatment/survival	66-68
interferon-a (Roferon-A®, Intron®)	102
interleukin-2 or IL-2 (aldesleukin®)	102
Intron®, Roferon-A® (interferon-a)	102



inulin	67
iodine - low iodine diet	236-239
Iressa® (gefitinib)	268
irinotecan (Camptosar®)	167,182,189,214,223
iron overload	161-162
ixabepilone (Ixempra®)	174
Ixempra® (ixabepilone)	174
K	
Kadcyla® (ado-trastuzumab emtansine)	113
Karnofsky Performance Status Scale	251
Keppra® (levetiracetam)	167
ketogenic diet	168,266
L lapatinib (Tykerb®)	175,268
late dumping syndrome	257,260
letrozole (Femara®)	103,175
Leukeran® (chlorambucil)	109,267
leukemia (nutrition complications and management)	89
leuprolide (Lupron®)	103,175
levetiracetam (Keppra®)	167
lifetime risk of developing cancer (cancer statistics)	9
Livingston-Wheeler Diet	65



lomustine systemic (Gleostine®, CeeNU®, CCNSB®)	167
low-iodine diet	236-239
lung cancer - chapter (medical nutrition therapy for lung cancer) - chemotherapy induced peripheral neuropathy and glutamine - medical treatments - nutrition intervention in advanced stages - nutrition needs - nutrition risk screening & assessment - risk factors	209-212 211 210 211 211 210 209
Lupron® (leuprolide)	103,175
lutein	67
lycopene	67,232
lymphedema	175
M macrobiotic diet macronutrient needs for adults	65 33-35
malabsorption	88-89,118
malnutrition - and cancer - clinical characteristics - definition - in esophageal cancer - in palliative/hospice settings - in pediatric oncology - malnutrition screening tool (MST) - malnutrition screening tool for cancer patients (MSTC) - malnutrition universal screening tool (MUST)	25 29-30 28 184 241-243 143-147 26 26 26
Matulane® (procarbazine hydrochloride)	167,269
MCT oil	265

Index: Oncology Nutrition for Clinical Practice	a dietetic practice group of the ear Academy of Nutrition right. and Dietetics
measuring outcomes of oncology nutrition programs	51
mechlorethamine (nitrogen mustard, Mustagen®)	109
medical nutrition therapy/nutrition intervention for - breast cancer - colorectal cancer - dumping syndrome - gastric cancer - head/neck cancer - neuroendocrine tumors - ovarian cancer - pancreatic cancer - prostate cancer - surgical issues (e.g., gastric transit abnormalities)	176 193 183,260-261 190 204,206 139 216-217 221 231
medicinal mushrooms	57
Megace® (megestrol acetate)	103
megestrol acetate (Megace®)	103
melatonin	70
melphalan (Alkeran®)	110,214,268
mercaptopurine (6-MP or Purinethol®)	110,268
metabolic changes in cancer	33
metastatic bone pain	107
Metastron® (strontium 89)	107
methotrexate (MTX)	11,111,160,174,182,202,268
micronutrients (also see dietary supplements)	35,56,69-72
mitomycin (Mutamycin®)	111,182,189,223
monoamine oxidase (MAO)	115,269
monoclonal antibodies	113,160
MTX (methotrexate)	11,111,160,174,182,202,268

	110
mucositis	119
Mutamycin® (mitomycin)	111,182,189,223
mycophenolate mofetil (Cellcept®)	160
Myleran® (busulfan)	109,267
National Comprehensive Cancer Network (NCCN) Cancer Survivors Guidelines	nip 97,249
nausea/vomiting	89,119, 260
Navelbine® (vinorelbine)	112,174,182,214
neuroendocrine tumors	139
Neurontin® (gabapentin)	167
Nexavar® (sorafenib)	189,269
nilotinib (Tasigna®)	268
Nipent® (pentostatin)	160
Nolvadex® (tamoxifen)	103,175,269
non-Hodgkin's lymphoma	88
nutraceuticals	56-57
nutrient absorption	187
nutrient requirements (including DRIs and RDAs) - calorie and protein requirements for pediatric HSCT patients - daily calcium requirements for children (RDAs) - daily vitamin D requirements (RDAs) - DRIs for estimating energy requirements for children - DRIs for protein intake for children - DRIs, RDAs, Als for macronutrients, fiber, and water for adults - Holliday Segar method for estimating fluid maintenance needs - protein requirements in health and disease (adults)	154 151 150 148-149 150 34 150 34



nutrigenomics and cancer - chapter	79-85
 carcinogenesis diet and nutrition recommendations for cancer prevention & survivorship epigenetics and cancer 	79-80 82 82
- future research	83
- glossary of terms	80
- genetic variation and cancer risk	81
- inherited cancer syndromes	81-82
- nutritional genomics (definition)	79
nutrition and cancer prevention	
- chapter	15-24
- AICR/WCRF personal recommendations	17
- alcoholic drinks	18-19
- anti-cancer nutrition	54-55
- body fatness/weight	15-16 19-20
breastfeedingdietary supplements	19-20
- energy density	16
- flaxseed	21
- green tea	21
- omega-3 fatty acids	20
- physical activity	16
- plant-based diet	16-18
- red and processed meats	18
- salt/sodium	19
- soy	20-21
nutrition and cancer survivorship	
- chapter	87-96
- biology of weight change in cancer survivors	91
- dietary guidance; a role for specific foods	92-93
- dietary interventions for bone and muscle health	93
- dietary intervention studies in cancer survivors	91-92
- dietary supplementation for survivors	93-94
- long-term nutrition related complications of common cancers	88-89
- obesity in the post-treatment setting	90-91
- resources for cancer survivors	90
- select randomized clinical trials addressing nutrition and cancer survivorship	92
- the cancer survivor	87
nutrition assessment	
- for patients with brain tumors	166

definitionfor hematopoietic cell transplantationfor patients with prostate cancer	27 157-158 233
- for pediatric patients - for surgical patients	151-152 135
nutrition diagnoses for long term nutrition related complications of cancer	88-89
nutrition impact symptoms - and quality of life - for agents used to treat brain tumors - for agents used to treat breast cancer - for chemotherapy agents used to treat head and neck cancer - for chemotherapy agents used to treat ovarian cancer - for treatments of GI cancers - for treatments of pancreatic cancer - prevalence in cancer patients - symptom management for nutrition impact symptoms	241-242 167 173 202 214 189 223 242 115-121
nutrition issues and outcomes across the cancer continuum	13
nutrition management for cancers of the GI tract: - chapter - introduction to GI cancers - nutrient needs for cancers of the GI tract - nutrition absorption in the GI tract - nutrition related effects of GI cancer treatments	187-199 187 187-188 187 189
anal cancer - medical treatments/nutrition implications - overview - risk factors	197 196 197
colorectal cancer (CRC) - diet and lifestyle recommendations for CRC survivors - medical nutrition therapy / nutrition management - medical treatments - overview - risk factors	193 192-193 191-192 191 191
gallbladder cancer - nutrition management - overview - risk factors - treatment options	196 195 195 196



gastric cancer - medical nutrition therapy - overview - risk factors - treatments	190 188 188-189 189-190
hepatocellular cancer - overview - risk factors - signs and symptoms - treatments	194 194 195 194-195
nutrition management of oncology patients in palliative and hospice settings - chapter - artificial nutrition and hydration - definitions - nutrition impact symptoms and quality of life - nutrition screening and assessment - nutrition support in advanced cancer	214-247 241-247 243-244 241 241-242 242-243 245
nutrition management of the surgical oncology patient - chapter - colorectal surgery - diet after intestinal surgery - esophageal surgery - head and neck surgery - long-term feeding/nutrition issues - pancreatic surgery - peritoneal surgery - post-operative nutrition issues - pre-operative nutrition issues and education - small bowel surgery - stomach surgery	135-142 138,192 253-255 137,183 136 140 139 136 136 135 138
nutrition-related (and long term) complications of common cancers by cancer site	88-89
nutrition risk screening and assessment of the oncology patient - chapter - effects of malnutrition on the oncology patient - evidence based nutrition assessment - malnutrition (definition/characteristics) - nutrition screening - screening tools validated for oncology patients	25-32 25 26-28 28-31 25-26 26

- screening & assessment in hospice/palliative care	242-243
- screening & assessment in lung cancer	210
- screening & assessment in ovarian cancer	215
- screening & assessment in pediatric cancers	151-152
- screening & assessment in prostate cancer	233
- screening & assessment in prostate cancer	233
nutrition support in the oncology setting	
- chapter	123-133
- administration of enteral feeding	125-135
<u> </u>	
- blenderized tube feeding recipes	132-133
- feeding routes and considerations (enteral nutrition)	124
- formulations and modular nutrients (enteral nutrition)	125
- gastrointestinal complications (enteral nutrition)	127
- lab and tolerance monitoring for parenteral nutrition	130
- macronutrients in parenteral nutrition solutions	128
- metabolic complications & potential corrections during EN therapy	126
- monitoring gastric residual volumes	126
- nutrition support in palliative care and end of life	131,243-244
- nutrition support for advanced cancer patients	245
- standard adult parenteral trace element additives	129
- standard adult parenteral vitamin additives	129
- standard parenteral electrolyte requirements	129
nutritional effects of cancer medications/treatments: chemotherapy, bid hormone therapy and radiation therapy (® = brand name)	otherapy,
hormone therapy and radiation therapy	otherapy, 97-113
hormone therapy and radiation therapy (® = brand name)	
hormone therapy and radiation therapy (® = brand name) - chapter	97-113
hormone therapy and radiation therapy (® = brand name) - chapter ado-trastuzumab emtansine (Kadcyla®)	97-113 113
hormone therapy and radiation therapy (® = brand name) - chapter ado-trastuzumab emtansine (Kadcyla®) anastrozole (Arimidex®)	97-113 113 103
hormone therapy and radiation therapy (® = brand name) - chapter ado-trastuzumab emtansine (Kadcyla®) anastrozole (Arimidex®) azacitidine (Vidaza®)	97-113 113 103 110
hormone therapy and radiation therapy (® = brand name) - chapter ado-trastuzumab emtansine (Kadcyla®) anastrozole (Arimidex®) azacitidine (Vidaza®) bendamustine (Treanda®)	97-113 113 103 110 109
hormone therapy and radiation therapy (® = brand name) - chapter ado-trastuzumab emtansine (Kadcyla®) anastrozole (Arimidex®) azacitidine (Vidaza®) bendamustine (Treanda®) bevacizumab (Avastin®)	97-113 113 103 110 109 101
hormone therapy and radiation therapy (® = brand name) - chapter ado-trastuzumab emtansine (Kadcyla®) anastrozole (Arimidex®) azacitidine (Vidaza®) bendamustine (Treanda®) bevacizumab (Avastin®) bicalutamide (Casodex®) bleomycin (Blenoxane®)	97-113 113 103 110 109 101 103
hormone therapy and radiation therapy (® = brand name) - chapter ado-trastuzumab emtansine (Kadcyla®) anastrozole (Arimidex®) azacitidine (Vidaza®) bendamustine (Treanda®) bevacizumab (Avastin®) bicalutamide (Casodex®) bleomycin (Blenoxane®) busulfan (Myleran®)	97-113 113 103 110 109 101 103 111
hormone therapy and radiation therapy (® = brand name) - chapter ado-trastuzumab emtansine (Kadcyla®) anastrozole (Arimidex®) azacitidine (Vidaza®) bendamustine (Treanda®) bevacizumab (Avastin®) bicalutamide (Casodex®) bleomycin (Blenoxane®) busulfan (Myleran®) capecitabine (Xeloda®)	97-113 113 103 110 109 101 103 111 109 110
hormone therapy and radiation therapy (® = brand name) - chapter ado-trastuzumab emtansine (Kadcyla®) anastrozole (Arimidex®) azacitidine (Vidaza®) bendamustine (Treanda®) bevacizumab (Avastin®) bicalutamide (Casodex®) bleomycin (Blenoxane®) busulfan (Myleran®) capecitabine (Xeloda®) carboplatin (Paraplatin®)	97-113 113 103 110 109 101 103 111 109
hormone therapy and radiation therapy (® = brand name) - chapter ado-trastuzumab emtansine (Kadcyla®) anastrozole (Arimidex®) azacitidine (Vidaza®) bendamustine (Treanda®) bevacizumab (Avastin®) bicalutamide (Casodex®) bleomycin (Blenoxane®) busulfan (Myleran®) capecitabine (Xeloda®) carboplatin (Paraplatin®) carmustine (BCNU®)	97-113 113 103 110 109 101 103 111 109 110 109
hormone therapy and radiation therapy (® = brand name) - chapter ado-trastuzumab emtansine (Kadcyla®) anastrozole (Arimidex®) azacitidine (Vidaza®) bendamustine (Treanda®) bevacizumab (Avastin®) bicalutamide (Casodex®) bleomycin (Blenoxane®) busulfan (Myleran®) capecitabine (Xeloda®) carboplatin (Paraplatin®) carmustine (BCNU®) cetuximab (Erbitux®)	97-113 113 103 110 109 101 103 111 109 110 109 109
hormone therapy and radiation therapy (® = brand name) - chapter ado-trastuzumab emtansine (Kadcyla®) anastrozole (Arimidex®) azacitidine (Vidaza®) bendamustine (Treanda®) bevacizumab (Avastin®) bicalutamide (Casodex®) bleomycin (Blenoxane®) busulfan (Myleran®) capecitabine (Xeloda®) carboplatin (Paraplatin®) carmustine (BCNU®) cetuximab (Erbitux®) chlorambucil (Leukeran®)	97-113 113 103 110 109 101 103 111 109 110 109 113 109
hormone therapy and radiation therapy (® = brand name) - chapter ado-trastuzumab emtansine (Kadcyla®) anastrozole (Arimidex®) azacitidine (Vidaza®) bendamustine (Treanda®) bevacizumab (Avastin®) bicalutamide (Casodex®) bleomycin (Blenoxane®) busulfan (Myleran®) capecitabine (Xeloda®) carboplatin (Paraplatin®) carmustine (BCNU®) cetuximab (Erbitux®) chlorambucil (Leukeran®) cisplatin (Platinol®, CDDP)	97-113 113 103 110 109 101 103 111 109 110 109 109 113 109
hormone therapy and radiation therapy (® = brand name) - chapter ado-trastuzumab emtansine (Kadcyla®) anastrozole (Arimidex®) azacitidine (Vidaza®) bendamustine (Treanda®) bevacizumab (Avastin®) bicalutamide (Casodex®) bleomycin (Blenoxane®) busulfan (Myleran®) capecitabine (Xeloda®) carboplatin (Paraplatin®) carmustine (BCNU®) cetuximab (Erbitux®) chlorambucil (Leukeran®) cisplatin (Platinol®, CDDP) cyclophosphamide (Cytoxan®, CTX)	97-113 113 103 110 109 101 103 111 109 110 109 113 109 109
hormone therapy and radiation therapy (® = brand name) - chapter ado-trastuzumab emtansine (Kadcyla®) anastrozole (Arimidex®) azacitidine (Vidaza®) bendamustine (Treanda®) bevacizumab (Avastin®) bicalutamide (Casodex®) bleomycin (Blenoxane®) busulfan (Myleran®) capecitabine (Xeloda®) carboplatin (Paraplatin®) carmustine (BCNU®) cetuximab (Erbitux®) chlorambucil (Leukeran®) cisplatin (Platinol®, CDDP) cyclophosphamide (Cytoxan®, CTX) cytarabine, ARA-C (Cytosar-U®)	97-113 113 103 110 109 101 103 111 109 110 109 113 109 109 109
hormone therapy and radiation therapy (® = brand name) - chapter ado-trastuzumab emtansine (Kadcyla®) anastrozole (Arimidex®) azacitidine (Vidaza®) bendamustine (Treanda®) bevacizumab (Avastin®) bicalutamide (Casodex®) bleomycin (Blenoxane®) busulfan (Myleran®) capecitabine (Xeloda®) carboplatin (Paraplatin®) carmustine (BCNU®) cetuximab (Erbitux®) chlorambucil (Leukeran®) cisplatin (Platinol®, CDDP) cyclophosphamide (Cytoxan®, CTX)	97-113 113 103 110 109 101 103 111 109 110 109 113 109 109

daunorubicin (Daunomycin®)	111
denosumab (Xgeva®, Prolia®)	113
docetaxel (Taxotere®)	112
doxorubicin (Adriamycin®)	111
doxorubicin liposomal (Doxil®)	111
epirubicin (Ellence®)	111
etoposide (Vepesid®, VP-16)	112
exemestane (Aromasin®)	103
fludarabine (Fludara®)	110
fluorouracil (5-FU)	110
flutamide (Eulexin®)	103
gemcitabine (gemzar®)	110
goserelin (Zoladex®)	103
ibritumomab tiuxetan (Zevalin®)	113
idarubicin (Idamycin®)	111
ifosfamide (Ifex®)	109
interferon-a (Roferon® or Intron A®)	102
interleukin-2 or IL-2 (Aldesleukin®)	102
letrozole (Femara®)	103
leuprolide acetate (Lupron®)	103
mechlorethamine (nitrogen mustard)	109
megestrol acetate (Megace®)	103
melphalan (Alkeran®)	110
megestrol acetate (Megace®)	103
mercaptopurine (6-MP)	110
methotrexate (MTX)	111
mitomycin-C (Mutamycin®)	111
oxaliplatin (Eloxatin®)	110
paclitaxel (Taxol®)	112
paclitaxel protein-bound (Abraxane®)	112
panitumumab (Vectibix®)	113
pertuzumab (Perjeta®)	113
pemetrexed (Alimta®)	111
radium 223 (Xofigo®)	107
raloxifene (Evista®)	103
rituximab (Rituxan®)	113
samarium 153 (Quadramet®)	107
strontium 89 (Metastron®)	107
tamoxifen (Novaldex®)	103
toremifene citrate (Fareston®)	103
temozolomide (Temodar®)	110
teniposide (Vumon®, VM-26)	112
thioguanine (6-TG)	111
thiotepa (Thioplex®)	110
trastuzumab (Herceptin®)	113

Index: Oncology Nutrition for Clinical Practice	a dietetic practice group of the Academy of Nutrition and Dietetics
vinblastine (Velban®)	112
vincristine (Oncovin®)	112
vinorelbine (Navelbine®)	112
nutritional effects of cancer treatments	
- brain tumors	167
- breast cancer	173
- esophageal cancer	182
- GI cancer	189
- head & neck cancer	202 214
ovarian cancerpancreatic and bile duct cancer	214
- parioreatic and blic duct carloci	220
nutritional management of the pediatric oncology patient	
- chapter	143-156
- cachexia	144
 integrative oncology for pediatrics malnutrition 	152 143-147
- nutrition needs	145,147-151
- pediatric hematopoietic stem cell transplant	153-154
- prevalence of common childhood cancers	143
- specialized nutrition support	153
- subjective global nutritional assessment for children	146-147
nutritional needs of the adult oncology patient	
- chapter	33-39
- adjusted body weight	38
- breast cancer survivors	176
- childhood cancers- conditions affecting vitamin/mineral levels	145,148-151 35
- conditions influencing indirect calorimetry	36
- dietary reference intakes	33
- esophageal cancer	184
- GI cancers	187-188
- hematopoietic cell transplantation (adults)	158
- hematopoietic cell transplantation (pediatrics)	154
lung cancermacronutrient needs	211 33-38
- metabolic changes in cancer	33-36
- micronutrient needs	35
- ovarian cancer	215
- predictive equations for energy needs	37
- refeeding syndrome	38



O obesity/energy balance and cancer	15-16, 42,44,54,90,93
oleic acid	70
omega-3 fatty acids - omega-3 fats and breast cancer - omega-3 fats and cancer prevention - omega-3 fats and nutrition/prostate cancer risk - omega-3 fats and nutrition recommendations for prostate of the omega-3 fat as a functional food - omega-3 fats as a nutraceutical - omega-3 fats in table of select drugs & supplement interactions	72 56
omega-9 fatty acids	230,232
oncology nutrition program in a cancer center - components - definition - guidelines for nutrition care - organization	47 47 48 48-49
Oncovin® (vincristine)	112,167,270
oral candidiasis	117
oral toxicity scale (WHO)	203
ovarian cancer - chapter - disease staging - medical nutrition therapy - medical treatments - nutrition impact symptoms of select therapies - nutrition risk screening and assessment - risk factors - survivorship	213-218 214 216-217 214 214 215 213 216
oxaliplatin (Eloxatin®)	110,182,189,223,268
oxcarbazepine (Trileptal®)	167
P paclitaxel (Taxol®)	2,174,182,189,202,214,223

paclitaxel protein-bound (Abraxane®)	112
palliative and hospice care - chapter - artificial nutrition and hydration - definitions - nutrition impact symptoms and quality of life - nutrition screening and assessment - nutrition support in advanced cancer	241-247 243-244 241 241-242 242-243 245
pancreatic and bile duct cancer - chapter - diabetes - gastric outlet/duodenal/small bowel obstruction - medical/surgical treatments - nutrition impact symptoms - nutrition needs - nutrition risk factors - pancreatic enzyme replacement products - pancreatic exocrine insufficiency - signs/symptoms of pancreatic exocrine insufficiency	219-227 224 225-226 221-222 221,223 220 220 225 224
pancreatic exocrine insufficiency and enzyme replacement	224-225
panitumumab (Vectibix®)	113,189,269
Paraplatin® (carboplatin)	109,182,189,202
parenteral nutrition - access - complications - components - hematopoietic cell transplantation - home setting - indications - initiation - monitoring - palliative setting - pediatrics - trace element and vitamin additives - transition to oral nutrition	127 130 128-129 159 130 127 129 129-130 131 153 129 130

pediatric oncology (also see nutritional management of the pediatric oncology	143-156 gy patient)
pemetrexed (Alimta®)	214,269
pentostatin (Nipent®)	160
performance status	251
Perjeta® (pertuzumab)	113,175
pertuzumab (Perjeta®)	113,175
phenytoin (Dilantin®)	167
physical activity - and cancer prevention - and cancer survivors - during cancer treatment - integrative oncology	16-17 43 44 54
plant based diet	16-17,54,61,230
plants and pharmaceuticals	68
Platinol® (cisplatin)	109,182,189,202,214,223,267
procarbazine hydrochloride (Matulane®)	167,269
Prograf®, Astagraf XL® (tacrolimus)	160
Prolia®, Xgeva® (denosumab)	113
prostate cancer - chapter - medical nutrition therapy - medical treatment - nutrition recommendations for survivors - nutrition screening and assessment - risk factors - stages of prostate cancer	229-234 231 230 232 233 229-231 229
protein targeted therapies	100-101
Provenge® (sipuleucel-T)	269



PSA screening and prostate cancer	229
psoralen + ultraviolet light (multiple brand names)	160
public health guidelines for cancer prevention/survivorship	249
Purinethol® (mercaptopurine or 6-MP)	110,268
Q Quadramet® (samarium 153)	107
quercetin	69-70
Qvar®, Beconase AQ® (beclomethasone dipropionate)	160
R radiation therapy - external beam radiation therapy - possible acute effects of site-specific radiation therapy - possible late side effects of radiation therapy	102-104 105 105
possible side effects of total body radiation therapyradioimmunotherapy agents	106 104
radium 223 (Xofigo®)	107
raloxifene (Evista®)	103
randomized controlled trials (RCTs) on antioxidant supplementation and cancer risk	71
randomized controlled trials (RCTs) on vitamin D/calcium supplements and colon, breast, and prostate cancer	71
Rapamune® (sirolimus)	160
raw food diet plan	65
red and processed meats	18,232
refeeding syndrome	38
regorafenib (Stivarga®)	189,269



resources - for cancer survivors - for dietary supplements	90 72
risk factors for cancer - anal cancer - breast cancer - colorectal cancer - esophageal cancer - gallbladder cancer - gastric cancer - head and neck cancer - hepatocellular cancer - lung cancer - ovarian cancer - prostate cancer - thyroid cancer	197 171 191 181-182 195 188 201 194 209 213 229-230 235-236
Rituxan® (rituximab)	113
rituximab (Rituxan®)	113
Roferon-A®, Intron® (interferon-a)	102
<u>S</u> salt/sodium	19,249
samarium 153 (Quadramet®)	107
Sandimmune® (cyclosporine)	160
selenium	231
side effects and nutritional implications of cytokines	102
side effects of brachytherapy (possible)	107
side effects of chemotherapy (specific drugs also listed under each drug's name) (additional information listed under symptom management)	109-112
side effects of monoclonal antibodies	113

Oncology Nutrition a dietetic practice group of the Academy of Nutrition

Index: Oncology Nutrition for Clinical Practice	a dietetic practice group of the Academy of Nutrition right. and Dietetics
side effects of radiation therapy (late effects)	105
side effects of radiopharmaceuticals for metastatic bone pain	107
side effects of site-specific radiation therapy (acute effects)	105
side effects of total body radiation	106
silymarin	76
sipuleucel-T (Provenge®)	269
sirolimus (Rapamune®)	160
sorafenib (Nexavar®)	189,269
soyfood	20,177,230,232
Sprycel® (dasatinib)	267
St. John's Wort	76, 267-270
standards of practice (SOP) in oncology nutrition care	49
standards of professional performance in oncology nutrition care	49
Stivarga® (regorafenib)	189,269
streptozocin (Zanosar®)	269
stress management	58
strontium 89 (Metastron®)	107
Sutent® (sunitinib)	269
surgical oncology (also see nutrition management of the surgical oncology patient)	135-142
sunitinib (Sutent®)	269
symptom management of cancer therapies - chapter - anorexia/poor appetite/early satiety - constipation	115-121 115 116

 diarrhea dysphagia fatigue malabsorption mucositis/esophagitis nausea/vomiting oral candidiasis taste and smell changes xerostomia/thick saliva 	116 117 118 118 119 119 117 120 120
<u>T</u> tacrolimus (Prograf®, Astagraf XL®)	160
tamoxifen (Nolvadex®)	103,175,269
Tarceva® (erlotinib)	223,267
Targretin® (bexarotene)	267
Tasigna® (nilotinib)	268
taste and smell changes	120
Taxol® (paclitaxel)	112,174,182,189,202,214,223
Taxotere® (docetaxel)	112,173,182,189,202,223
Tegretol® (carbamazepine)	167
Temodar® (temozolomide)	110,167,269
temozolomide (Temodar®)	110,167,269
temsirolimus (Torisel®)	269
teniposide (Vumon®, VM-26)	112
thalidomide (Thalomid®)	160,270
Thalomid® (thalidomide)	160,270
theanine	76
Thioplex® (thiotepa)	110

thioguanine (6-TG)	111
thiotepa (Thioplex®)	110
Thymoglobulin® (anti-thymocyte globulin)	160
Topamax® (topiramate)	167
topiramate (Topamax®)	167
topotecan (Hycamtin®)	182,214
toremifene citrate (Fareston®)	103
Torisel® (temsirolimus)	269
trastuzumab (Herceptin®)	113,175,182,189
Treanda® (bendamustine)	109
Trileptal® (oxcarbazepine)	167
tumor, lymph nodes, and metastasis (TNM) cancer staging system	9-10
thyroid cancer - chapter - low iodine diet - medical treatments - risk factors - types of thyroid cancer	235-240 236-239 236 235-236 236
tube feedings - blenderized tube feeding recipe - see enteral nutrition	132-133 123-127
Tykerb® (lapatinib)	175,268
$\underline{\underline{\textbf{U}}}$ Uceris®, Entocort EC® for oral; others for inhaled form (budesonide)	160
uterine cancer (uterine corpus)	88
ursodeoxycholic acid (over 20 brand names are available)	160



<u>V</u> Vectibix® (panitumumab)	113,189,269
vegetables/fruit	93,249,258,262
Velban® (vinblastine)	112,270
Velcade® (bortezomib)	267
Vepesid®, VP-16 (etoposide)	112,214
vinblastine (Velban®)	112,270
vincristine (Oncovin®)	112,167,270
vinorelbine (Navelbine®)	112,174,182,214
vitamin/mineral malabsorption	190
vitamin/mineral supplementation	69
vitamin A	267
vitamin B6	267-268
vitamin B12	269
vitamin C	71
vitamin D	56,70-72,230-232
vitamin E	71,231-232
VP-16, Vepesid® (etoposide)	112,214
Vumon® (teniposide, VM-26)	112
W/weight - and cancer outcomes	42
and prostate cancerduring treatment and post-treatment	231 43



- weight change in cancer survivors	43,88-89,91
World Health Organization Cancer Prevention Guideline	s 249
v.	
X Xeloda® (capecitabine)	110,173,182,189,214,223,267
xerostomia/thick saliva	120
Xgeva®, Prolia® (denosumab)	113
Xofigo® (radium 223)	107
7	
Zaltrap® (ziv-aflibercept)	189
Zanosar® (streptozocin)	269
Zevalin® (ibritumomab tiuxetan)	113
zinc	71
ziv-aflibercept (Zaltrap®)	189
Zoladex® (goserelin)	103,175
zoledronic acid (Zometa®)	270
Zometa® (zoledronic acid)	270